翻訳と辞書 |
LAG525
LAG525 is a monoclonal antibody being developed by Novartis for the treatment of cancer. The antibody targets the immune checkpoint LAG-3, which is expressed on T cells and tends to down-regulate an immune response. In a June 2015 presentation Novartis management indicated that 'dosing is imminent' for the first clinical trials of LAG525.〔(【引用サイトリンク】url=https://www.novartis.com/sites/www.novartis.com/files/2015-06-meet-the-management-2-pharma.pdf )〕 LAG525's first clinical trial is a Phase I in expected to be in patients with various solid tumors, in combination with PDR001, an anti-PD-1 monoclonal antibody. (ClinicalTrials.gov identifier NCT02460224). ==References==
抄文引用元・出典: フリー百科事典『 ウィキペディア(Wikipedia)』 ■ウィキペディアで「LAG525」の詳細全文を読む
スポンサード リンク
翻訳と辞書 : 翻訳のためのインターネットリソース |
Copyright(C) kotoba.ne.jp 1997-2016. All Rights Reserved.
|
|